Updated estimates of healthcare utilization and costs among perinatally HIV-infected children

Journal of Acquired Immune Deficiency Syndromes

Volumn 41, Issue 4, 2006, Pages 521-526

  Sansom, Stephanie L ^a,c   Anderson, John E ^a   Farnham, Paul G ^b   Dominguez, Kenneth ^a   Soorapanth, Sada ^a   Clark, Jill ^a   Sukalac, Thom ^a   Earp, Mary Jo ^a   Bohannon, Beverly ^a   Fowler, Mary Glenn ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b GEORGIA STATE UNIVERSITY   (United States)

^c MS E 45 ^*  (United States)

Author keywords

Healthcare utilization; Lifetime treatment costs; Perinatal HIV

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADOLESCENT; ARTICLE; COST OF ILLNESS; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MEDICAL RECORD; PERINATAL INFECTION; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SURVIVAL TIME; UNITED STATES;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; DELIVERY OF HEALTH CARE; DISEASE TRANSMISSION, VERTICAL; DRUG COSTS; HEALTH CARE COSTS; HIV INFECTIONS; HOSPITALIZATION; HUMANS; INFANT; INFANT, NEWBORN; UNITED STATES;

EID: 33646759255     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000191286.70331.7b     Document Type: Article

References (30)

1. Centers for Disease Control and Prevention. Revised recommendations for HIV screening of pregnant women. MMWR Morb Mortal Wkly Rep. 2001;50:59-86.
2. Cooper ER, Charurat M, Mofenson L, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr. 2002;29:484-494.
3. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994;331:1173-1180.
4. Gorsky RD, Farnham PG, Straus WL, et al. Preventing perinatal transmission of HIV: costs and effectiveness of a recommended intervention. Public Health Rep. 1996;111:335-341.
5. Mauskopf JA, Paul JE, Wichman DS, et al. Economic impact of treatment of HIV-positive pregnant women and their newborns with zidovudine: implications for HIV screening. JAMA. 1996;276:132-138.
6. Hsia DC, Fleishman JA, East JA, et al. Pediatric human immunodeficiency virus infection: recent evidence on the utilization and cost of health services. Arch Pediatr Adolesc Med. 1995;149:489-496.
7. Fleishman JA, Hellinger FJ. Trends in HIV-related inpatient admissions from 1993 to 1997: a seven-state study. J Acquir Immune Defic Syndr. 2001;28:73-80.
8. Bozzette SA, Joyce G, McCaffrey DF, et al., for the HIV Cost and Services Utilization Study Consortium. Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. N Engl J Med. 2001;344:817-823.
9. Mrus JM, Goldie SJ, Weinstein MC, et al. The cost-effectiveness of elective Cesarean delivery for HIV-infected women with detectable HIV RNA during pregnancy. AIDS. 2000;14:2543-2552.
10. Barnhart HX, Caldwell MB, Thomas P, et al. Natural history of human immunodeficiency virus disease in perinatally infected children: an analysis from the Pediatric Spectrum of Disease Project. Pediatrics. 1996;97:710-716.
11. Agency for Healthcare Research and Quality. Introduction to the HCUP Nationwide Inpatient Sample (NIS), 2003. Healthcare Cost and Utilization Project (HCUP). Rockville, MD. Available at: http://www. hcup-us.ahrq.gov/db/nation/ nis/NIS_Introduction_2003_v7.pdf.
12. Physicians' Desk Reference. Montvale, NJ: Medical Economics Co.; 2001.
13. Working Group on Antiretroviral Therapy and Medical Management of HIV-infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. March 24, 2005. Available at: http://aidsinfo. nih.gov/guidelines/pediatric/PED_11032005.pdf.
14. Drug Topics Red Book. Montvale, NJ: Medical Economics Co.; 2001.
15. CMS. Clinical laboratory fee schedule, April release. 2001. Available at: http://www.cms.hhs.gov/providers/pufdownload/labfee.
16. Centers for Disease Control and Prevention. 1994 Revised classification system for human immunodeficiency virus infection in children less than 13 years of age: official addenda: human immunodeficiency virus infection codes and official guidelines for coding and reporting ICD-9-CM. MMWR Recomm Rep. 1994;43:1-10.
17. Centers for Disease Control and Prevention. 1993 Revised classification system for HIV infection and expanded surveillance for case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992;41:1-19.
18. Mrus JM, Tsevat J. Cost effectiveness of interventions to reduce vertical transmission from pregnant women who have not received prenatal care. Med Decis Making. 2004;24:30-39.
19. Sansom S, Jamieson D, Farnham P, et al. Human immunodeficiency virus retesting during pregnancy: costs and effectiveness in preventing perinatal transmission. Obstet Gynecol. 2003;102:782-790.
20. Gold MR, Siegel JE, Russell LB, et al. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
21. Hellinger FJ, Encinosa WE. Antiretroviral therapy and health care utilization: a study of privately insured men and women with HIV disease. Health Serv Res. 2004;39:949-967.
22. Zaric GS, Bayoumi AM, Brandeau ML, et al. The cost effectiveness of voluntary prenatal and routine newborn HIV screening in the United States. J Acquir Immune Defic Syndr. 2000;25:403-416.
23. Immergluck LC, Cull WL, Schwartz A, et al. Cost-effectiveness of universal compared with voluntary screening for human immunodeficiency virus among pregnant women in Chicago. Pediatrics. 2000;105:E54.
24. Grobman WA, Garcia PM. The cost-effectiveness of voluntary intrapartum rapid human immunodeficiency virus testing for women without adequate prenatal care. Am J Obstet Gynecol. 1999;181:1062-1071.
25. Myers ER, Thompson JW, Simpson K. Cost-effectiveness of mandatory compared with voluntary screening for human immunodeficiency virus in pregnancy. Obstet Gynecol. 1998;91:174-181.
26. Stringer JS, Rouse DJ. Rapid testing and zidovudine treatment to prevent vertical transmission of human immunodeficiency virus in unregistered parturients: a cost-effectiveness analysis. Obstet Gynecol. 1999;94: 34-40.
27. HIV Research Network. Hospital and outpatient health services utilization among HIV-infected patients in care in 1999. J Acquir Immune Defic Syndr. 2002;30:21-26.
28. Rutstein RM, Gebo KA, Siberry GK, et al. Hospital and outpatient health services utilization among HIV-infected children in care 2000-2001. Med Care. 2005;43:31-39.
29. Hellinger FJ. The lifetime cost of treating a person with HIV. JAMA. 1993;270:474-478.
30. Holtgrave DR, Pinkerton SD. Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs. J Acquir Immune Defic Syndr. 1997;16:54-62.